Response to chemotherapy in Patients treated after progression to olaparib
| Overall response (n=127) | |||||
| CR | PR | SD | PD | NA | |
| PFI, months | |||||
| <6 | 1 (4.5%) | 1 (4.5%) | 3 (13.6%) | 16 (72.7%) | 1 (4.5%) |
| 6–12 | 2 (3.5%) | 3 (5.3%) | 10 (17.5%) | 34 (59.6%) | 8 (14.1%) |
| >12 | 3 (6.3%) | 11 (22.9%) | 13 (27.1%) | 13 (27.1%) | 8 (16.7%) |
CR, complete response; NA, not applicable; PD, progression disease; PFI, platinum-free interval; PR, partial response; SD, stable disease.;